Asset Management Ventures (AMV)
VC Fund
Palo Alto, United States
Asset Management Ventures (AMV) is a VC fund in Palo Alto focused on Health Care and Biotechnology. AMV is a venture capital firm investing in early-stage digital health, tech, and life sciences companies.
- Total investments:
- 150
- Last investment:
- Lead investor:
- 21%
- Fund size:
- $150M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Asset Management Ventures (AMV) invests in
Stages Asset Management Ventures (AMV) invests in
Countries Asset Management Ventures (AMV) invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $500k–$6M
- Series A
- $3M–$21M
- Series B
- $5M–$35M
Investment Focus
Industry
- Health Care 44 (29%)
- Biotechnology 23 (15%)
- Medical 20 (13%)
- Software 19 (13%)
- Medical Device 10 (7%)
Stage
- Series A 29 (19%)
- Seed 24 (16%)
- Series B 23 (15%)
- Funding Round 10 (7%)
- Series C 9 (6%)
Country
- United States 73 (49%)
- Cyprus 1 (1%)
- Ireland 1 (1%)
- Singapore 1 (1%)
- South Korea 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Rich Simoni
Managing Partner
|
Managing Partner | Total investments: 17 | Find email | |
Skip Fleshman
Partner
|
Partner | Total investments: 55 | Find email | |
Louis Lange
Partner
|
Partner | Total investments: 19 | Find email | |
|
Pitch Johnson
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Autonomize AI is a human-centric AI platform that learns from multi-structured clinical and biomedical data and pairs it with human context to aid decision-making and data discovery. They extract contextual information from multi-structured healthcare data, enrich with human know-how, and aid decision-making and data discovery. | $28M / Series A / Jun 12, 2025 | ||
| Outcomes4Me provides an AI-powered digital platform designed to assist cancer patients in managing their care. The platform integrates clinical guidelines, genomic data, and clinical trial information to offer personalized treatment options. Patients can access features such as symptom tracking, medication management, and tailored clinical trialmatching. Outcomes4Me also facilitates the organization and understanding of medical records, enabling users to make informed decisions in collaboration with their healthcare providers. The platform is developed in collaboration with experts in oncology and aims to support patients throughout their treatment journey. | $21M / Series A / May 29, 2025 | ||
| SeeQC is a semiconductor company developing commercially viable application-specific quantum computing systems for global businesses. The company combines classical and quantum technologies to address the efficiency, stability, and cost issues endemic to quantum computing systems. It integrates superconducting qubit chips, proprietary Single FluxQuantum (SFQ), SFQ-based 10-40 GHz superconductive classical co-processors, and application-specific integrated circuits (ASICs).SeeQC delivers a commercially scalable and cost-effective quantum computing solution, classical readout, control, error correction, and data processing functions must be integrated with a quantum processor. It applies classical and quantum technology through digital readout and control technology and through a unique chip-scale architecture. The company's quantum system provides the energy- and cost-efficiency, speed, and digital control required to make quantum computing useful and bring the first commercially-scalable, problem-specific quantum computing applications to market.SeeQC was established in 2018 and is headquartered in Elmsford, N.Y, USA, and also has facilities in London, UK, and Naples, Italy. | $30M / Series A / Jan 14, 2025 | ||
| Medsien offers comprehensive remote care management services powered by artificial intelligence, integrating various care management programs into a single platform. The company focuses on enhancing patient engagement and outcomes through personalized support and streamlined operations. Medsien's technology enables healthcare providers toefficiently manage chronic care, remote patient monitoring, and related services, ultimately improving the patient experience. | Convertible Note / Dec 01, 2024 | ||
| We are a one-stop-shop for cardiovascular health. Empower yourself with research-backed info on your heart condition and how to prevent progression. Connect with a certified healthcare professional via video chat, messaging, and goal-setting to stay accountable. Stay in control of your health journey with a single dashboard that combines key dataand behavior tracking. Share with ease. | $4.5M / Seed / Jul 01, 2024 | ||
| Basys.ai automates the process of prior authorization and utilization management to improve costs and timeliness for health plans/payers using an AI-based platform. The proprietary platform automates the process of encoding/digitizing the payer policies using machine learning, thus reducing the piloting timeline by up to 9 months. | $2.4M / Pre-Seed / Jul 07, 2023 | ||
| Autonomize AI is a human-centric AI platform that learns from multi-structured clinical and biomedical data and pairs it with human context to aid decision-making and data discovery. They extract contextual information from multi-structured healthcare data, enrich with human know-how, and aid decision-making and data discovery. | $4M / Seed / Apr 10, 2023 | ||
| SubjectWell is the risk-free clinical trials marketplace for patient recruitment | $35M / Series B / Oct 18, 2022 | ||
| Carta empowers hospitals to personalize the delivery of care to the individual needs of each patient. The approach Carta Healthcare is advocating and enabling is to: find past patients similar to the current one being treated; quantify what exactly happened to them during their journey through the hospital (this is where our model comes in) and;use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital. Carta was founded in 2017 and is based in Palo Alto, California, United States. | $20M / Series B / Jul 22, 2022 | ||
| Secure AI Labs helps businesses access proprietary data by protecting it during analysis. It protects data by digitally enforcing data-use policies and enable data owners control who, how, and where the data is used, even after sharing. The company's encrypted analytics platform keeps data and algorithms secure at every step. It providesbioinformatics and machine learning to develop AI models which users can access from a diverse library. Businesses can access data easily without the liability of working with personal or proprietary information.Secure AI Labs was founded on 2017 and is based in Cambridge, Massachusetts. | $4.7M / Seed / Jul 11, 2022 | ||
| See all 150 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Asset Management Ventures (AMV) invest in?
Asset Management Ventures (AMV) invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 150 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Asset Management Ventures (AMV)'s check size?
Asset Management Ventures (AMV) typically joins rounds of $500k–$6M at Seed, $3M–$21M at Series A and $5M–$35M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Asset Management Ventures (AMV) participates in.
How do I contact Asset Management Ventures (AMV)?
Public channels for Asset Management Ventures (AMV) include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Asset Management Ventures (AMV)?
The team at Asset Management Ventures (AMV) includes Rich Simoni (Managing Partner), Skip Fleshman (Partner) and Louis Lange (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
